The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin

På svenska

Author

  • M. Lindh
  • B. Arnholm
  • Per Björkman
  • K. Hellstrand
  • M. Lagging
  • S. Nilsson
  • T. Wahlberg
  • E. Wallmark
  • O. Weiland
  • R. Wejstal
  • J. Westin
  • Anders Widell
  • G. Norkrans
Show all

Summary, in English

The treatment durations for hepatitis C are guided by the analysis of hepatitis C virus (HCV) RNA in blood at certain time points. This multicentre, randomized open label trial evaluated the utility and performance of individualized treatment durations guided by viral decline rates in 103 patients with HCV genotype 1 infection. Pegylated interferon 2a and ribavirin were given as standard of care (SOC) for 24, 48 or 72weeks or as dynamic treatment (DT) for 2472weeks. The DT duration was based on the time point when log HCV RNA would reach 0 log copies/mL, as estimated by the second-phase decline. The rate of sustained virologic response was 63% for SOC and 54% for DT, but this difference was not significant in multiple regression analysis taking predictive factors such as interleukin-28B genotypes, age and baseline viremia into account (P=0.45). The mean required treatment time per cured patient was 51weeks for DT as compared with 58weeks for SOC (P=0.22) when given per protocol (n=95) and was significantly shorter (42 vs 51weeks) among patients who achieved undetectable HCV RNA (P=0.01). We conclude that DT was feasible and increased efficiency. The estimated time point for 0 log viral copies/mL is a new and quantitative response variable, which may be used as a complement to the qualitative variable rapid virologic response. The outcome parameter treatment weeks per cured patient could become a useful tool for comparing treatment efficiency also in the era of directly acting antivirals.

Department/s

Publishing year

2013

Language

English

Pages

82-89

Publication/Series

Journal of Viral Hepatitis

Volume

20

Issue

4

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Gastroenterology and Hepatology

Keywords

  • HCV
  • interferon
  • kinetics
  • ribavirin
  • therapy

Status

Published

Research group

  • Infectious Diseases Research Unit
  • Clinical Microbiology, Malmö

ISBN/ISSN/Other

  • ISSN: 1365-2893